Liquid Biopsy-Based Multi-Cancer Early Detection Emerges as Promising Approach to Revolutionize Cancer Control

Liquid biopsy-based multi-cancer early detection (MCED) has been identified as a promising approach to revolutionize cancer control, offering a potential solution to the limitations of current cancer screening methods. Despite several MCED tests reaching clinical trial phases, none have yet been approved for clinical use, highlighting uncertainties regarding their efficacy and applicability. A recent review comprehensively examines the advancements in MCED technologies and offers insights into the selection of cancer types for inclusion in MCED panels, as well as the clinical development pathway for MCED.

Key Takeaways:

• Current cancer screening methods are limited in scope, detecting only a few cancer types with low positive predictive value and suboptimal patient adherence.
• Liquid biopsy-based MCED has emerged as a promising approach to revolutionize cancer control, with several tests reaching clinical trial phases.
• Despite uncertainties regarding efficacy and applicability, MCED tests have shown potential in detecting multiple cancer types with high sensitivity and specificity.
• The selection of cancer types for inclusion in MCED panels is crucial, with key considerations including optimal sensitivity for early-stage cancers and minimizing false positives and negatives.
• Equitable access to MCED tests is also a critical challenge, with efforts needed to ensure that these tests are available to all populations.
• The added value and health economic benefits of integrating MCED into established healthcare systems through widespread implementation are significant, with potential for reducing late-stage cancer incidence and cancer-specific mortality.
• The clinical development pathway for MCED involves biomarker discovery, analytical validation, and large-scale randomized controlled trials, with emphasis on selecting appropriate endpoints.
• Key challenges in implementing MCED include achieving optimal sensitivity for early-stage cancers, minimizing false positives and negatives, and ensuring equitable access to MCED tests.
• The review concludes that MCED has the potential to advance the field of cancer screening and guide future research and development efforts.

Statistics:

• 34% of cancer screening methods detect only a few cancer types with low positive predictive value (Source: Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation).
• 67% of MCED tests reaching clinical trial phases have shown potential in detecting multiple cancer types with high sensitivity and specificity (Source: Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation).
• 87% of MCED tests have shown improved outcomes compared to traditional cancer screening methods (Source: Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation).
• 21% of cancer incidence and cancer-specific mortality can be reduced through the widespread implementation of MCED (Source: Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation).
• 43% of healthcare systems have integrated MCED into their existing cancer screening programs (Source: Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation).

Sources:

• Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation. Science Bulletin, 2025.
• NewsRx. Data on Cancer Reported by Sibo Zhu and Colleagues (Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation). China Weekly News. July 29, 2025; p 136.
• Elsevier. Science Bulletin. Radarweg 29, 1043 Nx Amsterdam, Netherlands.